Background: Prostate cancer (PCa) is a leading cause of tumor mortality in Western societies. In China, the PCa mortality rate is increasing yearly. Androgen receptors (ARs) and microRNAs (miRNAs) play central roles in prostate carcinogenesis and progression. Methods: To characterize the underlying molecular mechanisms, we compared the miRNA profiles of early PCa (G ≤ 7), advanced PCa (G > 7) and non-tumor prostate tissues using deep-sequencing. The target genes of differentially expressed miRNAs were predicted by bioinformatics analysis and confirmed by luciferase reporter assays and Western blot (WB) and quantitative reverse transcription-PCR (qRT-PCR)
Introduction
Prostate cancer (PCa) is the most common malignancy of the male genitourinary tract, and the second leading cause of cancer deaths among males in Western societies [1] . In the United States in 2013, it was estimated that 238,590 new PCa cases were diagnosed with 29,720 attributable deaths [2] . Androgen receptors (ARs) are one of the most important nuclear transcription factors among the steroid hormone receptor superfamily of genes. Normal prostate growth and development, prostate carcinogenesis, and castration-resistant progression of PCa are dependent on AR expression and function. Alterations in AR structure, expression and signaling could have a defining role in PCa progression. AR is translocated to the nucleus in a dimerized form and regulates gene expression by binding to specific hormone response elements [3] . In the early stages, PCa depends on androgens for growth; therefore, the most effective systemic treatment for this hormone sensitive cancer is androgen deprivation therapy. However, the greatest problem associated with this approach is that, after hormone treatment, the tumor inevitably progresses from an androgen-dependent (AD) form to an incurable castration-resistant (CR) form. Many of these AR-regulated genes are key regulators of prostate development and maintenance. AR signaling is also critical to the initiation and progression of PCa.
MicroRNAs (miRNAs) are small regulatory RNAs that target mRNAs and cause mRNA cleavage and/or translational suppression. They may function as oncogenes or tumor suppressors. Aberrant miRNA expression is closely associated with growth, development, invasion, metastasis, and prognosis of various cancers, including PCa. A number of miRNAs have been reported to be upregulated or downregulated in human PCa and are used as biomarkers for diagnosis, prognosis, and classification. MiR-141-3p is one of these upregulated miRNAs in PCa cells and upregulation of miR-141-3p has been demonstrated to be a biomarker for the disease [4] [5] [6] [7] [8] . Nevertheless, the mechanism by which aberrant miR-141-3p expression contributes to prostate tumorigenesis is still not fully understood.
Several miRNA profiling studies in PCa have been reported, but the results regarding the deregulation of miRNAs are highly inconsistent. We have previously reported deregulation of miRNAs in PCa revealed by deep-sequencing in a study designed to investigate the expression levels and roles of miR-141-3p in PCa carcinogenesis [9] . Expression levels of objective genes were measured by deep-sequencing and quantitative polymerase chain reaction (qPCR) in a small cohort of patients with localized early PCa (Gleason ≤ 7) and non-tumor control tissues [9] . In the present study, the expression levels of miR-141-3p and the ef-fects on AR transcriptional activity were estimated by upregulating or downregulating miR-141-3p using its mimic or inhibitor in the human non-malignant prostate epithelial cell line RWPE-1and human malignant prostate cancer cell lines PC-3 and VCaP. There were no differences in miR-141-3p expression in early PCa tissues compared to control benign prostatic hyperplasia (BPH) tissues. MiR-141-3p targeted the open reading frame (ORF) region of AR mRNA resulting in AR translational suppression and mRNA degradation and miR-141-3p expression correlated inversely with AR expression. Moreover, in vitro functional studies performed by upregulating or downregulating miR-141-3p expression using an artificial mimic or inhibitor showed that miR-141-3p overexpression suppressed cell proliferation and attenuated mobility in RWPE-1 cells. Our findings not only provide new insights into the mechanisms of prostate tumorigenesis, but also reveal a novel strategy for early PCa therapy.
Materials and Methods

Cell Culture
The immortalized benign prostatic epithelial cell line RWPE-1 and human malignant prostate cancer cell lines PC-3 and VCaP, were obtained from the American Type Culture Collection (ATCC), and maintained in regular medium supplemented with 10% fetal bovine serum (FBS) at 37˚C and under 5% CO 2 in a humidified incubator until 80% -90% confluence.
Oligonucleotides and Cell Transfection
MiR-141-3p mimic and inhibitor oligonucleotides (Biomics, Jiangsu China) were used at a 100 nM final concentration in the experiments. RWPE-1 cells were plated in 12-well plates at 1.5 -2.5 × 10 5 cells per well, grown for 24 h at 70% confluence, and then switched to antibiotic free media prior to transfection.
Next, 5 µL oligos and 4.8 µL X-tremeGENE 9 DNA Transfection Reagent (Roche, Basel Switzerland) were added individually to 100 µL Opti-MEM (Invitrogen, Carlsbad USA), and then incubated for at least 20 min before being added to the cultured cells. The overexpression and inhibition of miR-141-3p
were achieved by transfection of commercial mature miRNA and antisense miRNA with an appropriate miRNA control. The cells were incubated with the aforementioned oligonucleotides after 48 -72 h. After transient transfection, total RNA extraction, genetic and functional characteristics were analyzed by qRT-PCR and WB.
RNA Isolation and qRT-PCR Analysis
For quantitative expression analyses of mRNA and miRNA, total RNAs were isolated from Formalin-Fixed and Parrffin-Embedded (FFPE) prostatic tissues ( 
Western Blotting
Transfected cells were lysed in radio-immunoprecipitation assay (RIPA) buffer (Thermo Scientific) supplemented with protease inhibitors (100 mM Tris-HCl at pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% deoxycholate acid, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 2 mM DTT, 2 mM leupeptin, and 2 mM pepstatin). Lysates were centrifuged at 12,000 rpm for 10 min under 4˚C, and supernatants containing total proteins were collected. Protein concentrations were determined by the BCA method (Beyotime, Jiangsu China), and aliquots of 20 µg protein lysates were separated by SDS-polyacrylamide gel electrophoresis and then transferred to PVDF membranes (GE Healthcare Life Sciences, USA). Membranes were blocked with 5% non-fat milk solution for 2 h. Immunoblotting was performed using an antirabbit AR monoclonal antibody (diluted 1:1,000; Abcam, ER179(2)). GAPDH immunoblotting was performed using an anti-rabbit GAPDH antibody (Abcam, EPR6256). The secondary antibody was goat anti-rabbit HRP-linked (Abcam, ab6721), and blots were developed using enhanced chemiluminescence Detection System (Thermo Scientific). Protein levels were quantified using ImageJ2× software and normalized to GAPDH levels.
Luciferase Reporter Assays
To construct reporter plasmids, a DNA fragment of the AR ORF containing the putative miR-141-3p binding site (5'-GCCATTGAGCCAGGTGTAGTGTG-3') was amplified by PCR from human cDNA. The AR ORF fragment lacking the miR-141-3p binding site (5'-GCCA-------AG-3') was used as negative control. following the manufacturers' instructions. Luciferase activities were expressed as the ratio of firefly to Renilla luciferase activity and normalized to the levels detected in control transfections.
Cell Proliferation Assay
To assess the contribution of miR-141-3p to PCa cell proliferation, transiently transfected RWPE-1 cells were seeded into 96-well plates (3000 cells/well). Cells 
Cell Cycle Assay
Cells were plated in 12-well plates (1.5 -2. 
Wound-Healing Assay
Transfected cells were cultured to 80% -90% confluence in 6-well plates. Cell layers were scratched using a 10 µL pipette tip to form wound gaps and then 
Bioinformatics
Potential miR-141-3p targets were predicted and analyzed using the following four publicly available algorithms: RNAhybrid 
Statistical Analysis
Statistical analyses of data were performed with SPSS 20.0. All data are expressed as the mean ± SD of at least three separate experiments. All statistical tests were two-sided, and P-values < 0.05 were considered to indicate statistical significance. Unless otherwise noted, the differences between groups were analyzed using either the unpaired Student's t-test when only two groups were compared or a one-way analysis of variance (ANOVA) when more than two groups were compared.
Results
Aberrant Expression of miR-141-3p in Human Early PCa
We previously investigated small RNA transcriptomes by deep-sequencing technology to evaluate three pooled libraries [9] . A total of 13,896,705, 16,768,094 and 17,184,337 raw sequence reads were produced for the malignant PCa (G > 7), early PCa (G ≤ 7), and BPH groups, respectively. After filtering out low quality reads and trimming off adaptors, 10,494,173, 14,577,221 and 14,614,835 sequence reads were obtained [9] . The normalized counts of sequencing reads (specific miRNA/total sequencing tags in the library) were used to quantify miRNA expression levels among the PCa (G > 7), PCa (G ≤ 7) and BPH groups. The statistical significance (P-value) was inferred based on the Bayesian method, which was developed for analysis of digital gene expression profiles. We found a 1.26-fold reduction in miR-141-3p expression in early PCa compared to BPH (P < 0.05), while compared to the early PCa samples, the av- (Figure 1(b) ). This may be due to the limited number of cases analyzed. Taken together, these data provide evidence that miR-141-3p expression is not evidently changed in early PCa. 2585 bp of the AR mRNA (GenBank: M23263.1) was a potential miR-141-3p binding site (Figure 2(a) ). Sequence alignment of this putative site showed evolutionary conservation within mammalian species and AR mutants ( Table 1) .
AR Is a Direct
To verify that the putative miR-141-3p binding site in the ORF of AR mRNA is responsible for regulation by miR-141-3p, the region spanning 2550 -3000 bp of the AR ORF (5'-GCCATTGAGCCAGGTGTAGTGTG-3') and its mutant (5'-GCCA-------AG-3') were cloned separately into the pmirGLO luciferase reporter vector, and then cotransfected with the miR-141-3p mimic or control miR-NC into 293T cells. Luciferase activity was measured after two days. As shown in Figure 2(b) , the miR-141-3p mimic significantly reduced luciferase levels when cotransfected with the wild-type AR ORF (8.9% inhibition, P < 
MiR-141-3p Inhibits Prostate Epithelial Cell Proliferation and Mobility
To analyze the role of miR-141-3p in early progression of human PCa, we upregulated or downregulated miR-141-3p to observe its influence on cell proliferation, cell cycle and mobility ability. We chose immortalized normal human prostatic epithelial cell line RWPE-1 cells to study the functions of miR-141-3p, because the genome and phenotype of these cells are similar to those of normal prostatic epithelial cells. In this cellular system, we were able to reproduce the development process of early PCa induced by miR-141-3p and AR. RWPE-1 cells were transfected with the miR-141-3p mimic or miR-NC, and analyzed for cell growth, cell cycle and mobility. MiR-141-3p-transfected RWPE-1 cells expressed the miRNA at a level 106-fold higher than that of the control ( Figure   2(c) ). Proliferation assays showed that cell growth was reduced in miR-141-3p-transfected cells compared with miR-NC-transfected control cells (Figure 3(a) ).
In FCM analysis, the percentage of cells in the G0/G1 phase increased from 73.29% in controls to 75.75% in miR-141-3p-transfected cells, whereas the percentage of cells in S phase decreased from 18.70% to 16.20% (Figure 3(b) ), indicating that miR-141-3p overexpression effectively inhibited the transition from G 0 /G 1 to G2-S-M phase in the progression of human early PCa. We analyzed the effect of miR-141-3p overexpression on the mobility behavior of RWPE-1 cells.
MiR-141-3p overexpression decreased the mobility of cells (Figure 4) . In loss experiments of miR-141-3p, miR-141-3p knockdown led to enhanced cell growth and mobility as shown in Figure 3 and Figure 4 . To further evaluate the association of miR-141-3p with PCa progression, we chose two human malignant prostate cancer cell lines PC-3 and VCaP to assay their cell growth, cell cycle and mobility. As shown in Figure 3 and Figure 4 , the same alteration was observed, but miR-141-3p's effection to cell functions in PC-3 and VCaP cells was slightly compared to that in RWPE-1 cells.
Discussion
Although the prostate is dependent on androgens for growth and development, certain growth restriction mechanisms exist in the normal state to avert androgen-induced over-growth. It is imperative to reveal how AR mediates these actions and breaks the growth restriction mechanisms, leading to prostate carcinogenesis. Thus, in this study, we attempted to systematically identify miRNAs that bridge the AR pathways to exert the cellular phenotypic effect in PCa. To study how miRNAs regulate AR signaling, it is necessary to identify their targets. [15] reported that miR-141-3p expression is at normal levels in early PCa, which is in accordance with our findings. Using deep-sequencing analysis, we found that miR-141-3p expression was decreased by 1.26-fold in early PCa compared to that in BPH (P < 0.05), and confirmed a similar 1.17-fold decrease in early PCa compared to that in BPH (P = 0.2053) by qRT-PCR. In addition, miR-141-3p expression levels vary in different tumors, with overexpression observed in bladder [16] , urothelial [17] , breast [18] [19], ovarian [20] , endometrioid [21] , cholangiocytes [22] and colorectal cancers [23] and NSCLC [24] , while expression is downregulated in gastric cancer [25] , hepatocellular carcinomas [26] [27], renal cell carcinoma [28] , lymphatic metastatic pancreatic cancer [29] , pituitary tumors [30] , craniopharyngioma [31] , head and neck cancer [32] , osteosarcoma [33] , and cutaneous T cell lymphoma [34] . These reports provide compelling evidence for a role of miR-141-3p as an oncogene or tumor suppressor in different tumors and at different stages.
The results of our biological experimental validation reveal several interesting and novel mechanisms that significantly contribute to PCa cell survival and pathogenesis. Our present study also revealed some possible mechanisms by which androgen growth restriction is disrupted. Although we focus on AR in this study, we realize that miR-141-3p targets hundreds of human genes (Table 2) , Table 2 . Validated target genes of miR-141-3p.
MicTarBase 4.5 TarBase 7.0   ACVR2B, BAP1, BRD3, CDYL, CLOCK, CTBP2, DLX5, E2F3,  EIF4E, ELAVL4, ELMO2, ERBB2IP, HMGB1, HOXB5, KLF5,  KLF11, KLHL20, MAP2K4, MAPK9, MAPK14, NR0B2, PPARA,  PTEN, PTPRD, RASSF2, RIN2, SEPT7, SERBP1, SFPQ, SHC1,  SIP1, STK3, TCF7L1, TFDP2, TGFB2, TRAPPC2P1, UBAP1,  VAC14, WDR37, YWHAG, ZEB1, ZEB2, ZFPM2,   BAP1, BRD3, CLOCK, CyclinD1, DP2, E2F3, ELMO2, ERBB2IP,  HOXB5, HuD, JNK2, KLF5, KLF11, KLHL20, MAP4K4, PTEN,  PTPRD, RASSF2, RIN2, SEPT7, SFPQ, SHC1, STK3, TCF7L1,  TGFB2, UBAP1, VAC14, WDR37, YWHAG, ZEB1, ZEB2 Lineation emphasized target genes which are recorded by two databases.
and other targets may also be relevant in the tumor suppressive function of miR-141-3p in PCa. Although AR was the predicted as a direct target of miR-141-3p according to our data, PTEN and TCF7L1, which are involved in G1/S progression, and E2F3, which is involved in cell proliferation, have also been identified as miR-141-3p targets, and may also be involved in the PCa signaling pathways.
Conclusion
In this study, we show that miR-141-3p expression does not change in early
PCas. MiR-141-3p negatively regulates AR expression, and miR-141-3p down regulation increases expression of AR. Therefore, we propose that deregulation of miR-141-3p contributes to the high levels of AR expression in clinical PCas.
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